Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome

Endocrine

Volumn 41, Issue 3, 2012, Pages 450-457

  Goncalves J P ^a,b   Oliveira, A ^a,b   Severo, M ^a,b   Santos, A C ^a,b   Lopes, C ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Incidence rate ratio; Metabolic syndrome; Prevalence rate; Uric acid

Indexed keywords

TRIACYLGLYCEROL; URIC ACID;

AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERURICEMIA; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; PORTUGAL; PRIORITY JOURNAL; RANDOMIZATION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84862648876     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9629-8     Document Type: Article

References (48)

1. D. Conen, V. Wietlisbach, P. Bovet, C. Shamlaye, W. Riesen, F. Paccaud, M. Burnier, Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 4, 9 (2004). doi:10.1186/1471-2458-4-9
2. A.C. Gagliardi, M.H. Miname, R.D. Santos, Uric acid: a marker of increased cardiovascular risk. Atherosclerosis 202(1), 11-17 (2009). doi:10.1016/j.atherosclerosis.2008.05.022
3. T. Montalcini, G. Gorgone, C. Gazzaruso, G. Sesti, F. Perticone, A. Pujia, Relation between serum uric acid and carotid intimamedia thickness in healthy postmenopausal women. Intern. Emerg. Med. 2(1), 19-23 (2007). doi:10.1007/s11739-007-0004-3
4. T. Nakagawa, P. Cirillo, W. Sato, M. Gersch, Y. Sautin, C. Roncal, W. Mu, L.G. Sanchez-Lozada, R.J. Johnson, The conundrum of hyperuricemia, metabolic syndrome, and renal disease. Intern. Emerg. Med. 3(4), 313-318 (2008). doi:10.1007/s11739-008-0141-3
5. J. Lee, D. Sparrow, P.S. Vokonas, L. Landsberg, S.T. Weiss, Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am. J. Epidemiol. 142(3), 288-294 (1995)
6. W. Rathmann, B. Haastert, A. Icks, G. Giani, J.M. Roseman, Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur. J. Epidemiol. 22(7), 439-445 (2007). doi: 10.1007/s10654-007-9132-3 (Pubitemid 47224907)
7. D.I. Feig, D.H. Kang, R.J. Johnson, Uric acid and cardiovascular risk. N. Engl. J. Med. 359(17), 1811-1821 (2008). doi:10.1056/NEJMra0800885
8. R.J. Johnson, D.I. Feig, J. Herrera-Acosta, D.H. Kang, Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45(1), 18-20 (2005). doi:10.1161/01.HYP.0000150785.39055.e8 (Pubitemid 40066407)
9. M. Cigolini, G. Targher, M. Tonoli, F. Manara, M. Muggeo, G. De Sandre, Hyperuricaemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women. Int. J. Obes. Relat. Metab. Disord. 19(2), 92-96 (1995)
10. T. Nakagawa, K.R. Tuttle, R.A. Short, R.J. Johnson, Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 1(2), 80-86 (2005). doi:10.1038/ncpneph0019
11. K. Masuo, H. Kawaguchi, H. Mikami, T. Ogihara, M.L. Tuck, Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42(4), 474-480 (2003) (Pubitemid 37237341)
12. A. Dehghan, M. van Hoek, E.J. Sijbrands, A. Hofman, J.C. Witteman, High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31(2), 361-362 (2008). doi:10.2337/dc07-1276 (Pubitemid 351213351)
13. T. Wang, Y. Bi, M. Xu, Y. Huang, Y. Xu, X. Li, W. Wang, G. Ning, Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. Endocrine 40(1), 109-116 (2011). doi:10.1007/s12020-011-9449-2
14. M. Alderman, K.J. Aiyer, Uric acid: role in cardiovascular disease and effects of losartan. Curr. Med. Res. Opin. 20(3), 369-379 (2004). doi:10.1185/030079904125002982 (Pubitemid 38339177)
15. M. Schachter, Uric acid and hypertension. Curr. Pharm. Des. 11(32), 4139-4143 (2005) (Pubitemid 41672463)
16. Y.Y. Sautin, T. Nakagawa, S. Zharikov, R.J. Johnson, Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293(2), C584-C596 (2007). doi:10.1152/ajpcell.00600.2006 (Pubitemid 47235197)
17. K.J. Cheung, I. Tzameli, P. Pissios, I. Rovira, O. Gavrilova, T. Ohtsubo, Z. Chen, T. Finkel, J.S. Flier, J.M. Friedman, Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab. 5(2), 115-128 (2007). doi:10.1016/j.cmet.2007.01.005 (Pubitemid 46187493)
18. T. Nakagawa, H. Hu, S. Zharikov, K.R. Tuttle, R.A. Short, O. Glushakova, X. Ouyang, D.I. Feig, E.R. Block, J. Herrera-Acosta, J.M. Patel, R.J. Johnson, A causal role for uric acid in fructoseinduced metabolic syndrome. Am J Physiol Renal Physiol 290(3), F625-F631 (2006). doi:10.1152/ajprenal.00140.2005 (Pubitemid 43724964)
19. W.Y. Lin, C.S. Liu, T.C. Li, T. Lin, W. Chen, C.C. Chen, C.I. Li, C.C. Lin, In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study). Ann. Rheum. Dis. 67(3), 432-433 (2008). doi:10.1136/ard.2007.073601 (Pubitemid 351281289)
20. N. Ishizaka, Y. Ishizaka, E. Toda, R. Nagai, M. Yamakado, Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler. Thromb. Vasc. Biol. 25(5), 1038-1044 (2005). doi:10.1161/01.ATV.0000161274.87407.26 (Pubitemid 40627852)
21. T. Wilsgaard, B.K. Jacobsen, Lifestyle factors and incident metabolic syndrome. The Tromso Study 1979-2001. Diabetes Res. Clin. Pract. 78(2), 217-224 (2007). doi:10.1016/j.diabres.2007.03.006 (Pubitemid 47451522)
22. S. Ryu, J. Song, B.Y. Choi, S.J. Lee, W.S. Kim, Y. Chang, D.I. Kim, B.S. Suh, K.C. Sung, Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann. Epidemiol. 17(4), 245-252 (2007). doi:10.1016/j.annepidem.2006.10.001 (Pubitemid 46454381)
23. J. Tong, E.J. Boyko, K.M. Utzschneider, M.J. McNeely, T. Hayashi, D.B. Carr, T.M. Wallace, S. Zraika, F. Gerchman, D.L. Leonetti, W.Y. Fujimoto, S.E. Kahn, Intra-abdominal fat accumulation predicts the development of the metabolic syndrome in non-diabetic Japanese-Americans. Diabetologia 50(6), 1156-1160 (2007). doi:10.1007/s00125-007-0651-y (Pubitemid 46701558)
24. A.C. Santos, M. Severo, H. Barros, Incidence and risk factors for the metabolic syndrome in an urban South European population. Prev. Med. 50(3), 99-105 (2010). doi:10.1016/j.ypmed.2009.11.011
25. E. Ramos, C. Lopes, H. Barros, Investigating the effect of nonparticipation using a population-based case-control study on myocardial infarction. Ann. Epidemiol. 14(6), 437-441 (2004). doi:10.1016/j.annepidem.2003. 09.013 (Pubitemid 38916573)
26. Organization, W.H.: Guidelines for ATC classification. Collaborating centre for drug statistics methodology. Nordic Council on Medicines. WHO. (1990)
27. M.C. Horchberg, J.S. Smolen et al., Rheumatology, 3rd edn. (Mosby, New York, 2003)
28. C. Lopes, A. Aro, A. Azevedo, E. Ramos, H. Barros, Intake and adipose tissue composition of fatty acids and risk of myocardial infarction in a male Portuguese community sample. J. Am. Diet. Assoc. 107(2), 276-286 (2007). doi:10.1016/j.jada.2006.11.008 (Pubitemid 46136124)
29. Lopes, C.: Reproducibility and validity of a semi-quantitative food frequency questionnaire. In Diet and acute myocardial infarction: a population based case-control study. PhD thesis. University of Porto, Porto, 79-115 2000
30. M. Camoes, M. Severo, A.C. Santos, H. Barros, C. Lopes, Testing an adaptation of the EPIC physical activity questionnaire in Portuguese adults: a validation study that assesses the seasonal bias of self-report. Ann. Hum. Biol. 37(2), 185-197 (2010). doi: 10.3109/03014460903341836
31. S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr, J.A. Spertus, F. Costa, Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735-2752 (2005). doi:10.1161/CIRCULATIONAHA.105.169404 (Pubitemid 41532612)
32. K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, W.P. James, C.M. Loria, S.C. Smith Jr, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640-1645 (2009). doi:10.1161/ CIRCULATIONAHA.109.192644
33. L.Y. Chen, W.H. Zhu, Z.W. Chen, H.L. Dai, J.J. Ren, J.H. Chen, L.Q. Chen, L.Z. Fang, Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B 8(8), 593-598 (2007). doi:10.1631/jzus.2007.B0593
34. W. Rathmann, E. Funkhouser, A.R. Dyer, J.M. Roseman, Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann. Epidemiol. 8(4), 250-261 (1998) (Pubitemid 28208943)
35. H. Vuorinen-Markkola, H. Yki-Jarvinen, Hyperuricemia and insulin resistance. J. Clin. Endocrinol. Metab. 78(1), 25-29 (1994) (Pubitemid 24026741)
36. C. Russo, O. Olivieri, D. Girelli, P. Guarini, R. Corrocher, Relationships between serum uric acid and lipids in healthy subjects. Prev. Med. 25(5), 611-616 (1996). doi:10.1006/pmed.1996.0096 (Pubitemid 26315234)
37. Y. Moriwaki, T. Yamamoto, S. Takahashi, Z. Tsutsumi, K. Higashino, Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia. Ann. Rheum. Dis. 54(5), 351-354 (1995)
38. F. Cardona, F.J. Tinahones, E. Collantes, A. Escudero, E. Garcia- Fuentes, F.J. Soriguer, The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatology (Oxford) 42(3), 468-472 (2003) (Pubitemid 36367539)
39. J.M. Boer, C. Ehnholm, H.J. Menzel, L.M. Havekes, M. Rosseneu, D.S. O'Reilly, L. Tiret, Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. The EARS Study. European Atherosclerosis Research Study. Arterioscler. Thromb. Vasc. Biol. 17(9), 1675-1681 (1997) (Pubitemid 27423986)
40. A. Bedir, M. Topbas, F. Tanyeri, M. Alvur, N. Arik, Leptin might be a regulator of serum uric acid concentrations in humans. Jpn. Heart J. 44(4), 527-536 (2003) (Pubitemid 41518990)
41. O. Bosello, M. Zamboni, Visceral obesity and metabolic syndrome. Obes. Rev. 1(1), 47-56 (2000)
42. J.P. Forman, H. Choi, G.C. Curhan, Plasma uric acid level and risk for incident hypertension among men. J. Am. Soc. Nephrol. 18(1), 287-292 (2007). doi:10.1681/ASN.2006080865 (Pubitemid 46053441)
43. P.B. Mellen, A.J. Bleyer, T.P. Erlinger, G.W. Evans, F.J. Nieto, L.E. Wagenknecht, M.R. Wofford, D.M. Herrington, Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 48(6), 1037-1042 (2006). doi:10.1161/01.HYP.0000249768. 26560.66 (Pubitemid 44772705)
44. A. Shankar, R. Klein, B.E. Klein, F.J. Nieto, The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J. Hum. Hypertens. 20(12), 937-945 (2006). doi:10.1038/sj.jhh. 1002095 (Pubitemid 44782827)
45. J. Lee, Odds ratio or relative risk for cross-sectional data? Int. J. Epidemiol. 23(1), 201-203 (1994) (Pubitemid 24088622)
46. O. Axelson, M. Fredriksson, K. Ekberg, Use of the prevalence ratio v the prevalence odds ratio in view of confounding in cross sectional studies. Occup. Environ. Med. 52(7), 494 (1995)
47. P. Neil, Effect measures in prevalence studies. Environ. Health Perspect. 112(10), 1047-1050 (2004)
48. M.L. Thompson, J.E. Myers, D. Kriebel, Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup. Environ. Med. 55(4), 272-277 (1998) (Pubitemid 28179979)